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Inflammatory bowel diseases are chronic diseases affecting the gastrointestinal tract, whosemajor forms are represented by Crohn’s
disease (CD) and ulcerative colitis (UC). Their etiology is still unclear, although several factors have been identified as major
determinants for induction or relapses. Among these, the role of the “forgotten organ”, gutmicrobiota, has becomemore appreciated
in recent years. The delicate symbiotic relationship between the gut microbiota and the host appears to be lost in IBD. In this
perspective, several studies have been conducted to assess the role of prebiotics and probiotics in gut microbiota modulation. This
is a minireview aimed to address in an easy format (simple questions-simple answers) some common issues about the theme. An
update on the role of selected constituents of gut microbiota in the pathogenesis of IBD is presented together with the analysis of
the efficacy of gut microbiota modulation by prebiotics and probiotics administration in the management of IBD.
1. Introduction
The human microflora, known as “microbiota”, includes
bacteria, fungi, bacteriophages, and viruses and acts as an
“organ” synergistically with the host, creating an ecosystem.
It is able to colonize skin, the genitourinary system, the
respiratory system, and, above all, the gut.
Gut microbiota includes around a thousand different
species and more than 15,000 different strains of bacteria,
for a total weight of about 1 Kg. Stomach and small intestine
are relatively poor of bacteria, whilst the colon hosts about
1012 microorganisms [1], mainly belonging to the Firmicutes
and Bacteroidetes phyla [2]. Other domains represented are
those of Archaea [3] and Eukarya, plus many viruses and
bacteriophages [4].Gutmicrobiota is harbored also by several
yeast families, whose role in gastrointestinal physiology as
well as in diseases still remains unclear.
Since most species seem to be refractory to cultivation
with usual methods, culture-independent molecular tech-
niques, such as 16S rDNA genotyping, are used to charac-
terize the gut microflora from both fecal samples and bowel
biopsies [5–8].
At birth, the human gut is sterile, and the first coloniza-
tion occurs during childbirth and the first feed. Subsequently,
the microbiota changes under the influence of age, sex, state
of immune maturation, and environmental factors. After the
first two years, themicrobiota becomesmore stable, although
a stable endogen flora could be differentiated by a transient
one, which is, on the contrary, more sensitive to external
stimuli, as the gut mucosa is the first line of communication
with exogenous agents [9, 10].
During the first years of life, gut microbiota stimulates
the innate immunity, by inducing gut-associated lymphoid
system, and the acquired immunity, by stimulating specific
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systemic and local immune responses [11]. In the gut, bac-
terial fragments stimulate specific receptors, like TLR9 (toll-
like receptor 9, expressed on epithelial and immune cells) and
the inflammasome that are able to recognize bacterial DNA
[12].
In normal conditions, stimulation of the mucosal
immune system by gut microbiota determines a state of
“low-grade physiological inflammation” [13], a status of
continues activation of the mucosal immune system in
response to commensals, and, in case of needs, also towards
pathogens. Mucosal homeostasis requires a continuous
balance between pro- and anti-inflammatory components.
In recent years several studies investigated the correlation
between dysbiosis and intestinal and extraintestinal diseases,
including immune system alteration, obesity, allergies,
autoimmune diseases, irritable bowel syndrome (IBS), and
inflammatory bowel disease (IBD) [14, 15].
IBD are chronic, relapsing, multifactorial conditions
affecting the digestive tract. These majorly include ulcerative
colitis (UC) and Crohn’s disease (CD). Although the etiology
of these diseases is still unclear, the main hypothesis is
that IBD are a result of an excessive immune response to
endogenous bacteria, which occurs in genetically predis-
posed individuals [16, 17].
Most of conventional IBD therapies aim to modulate
immune system. 5-aminosalicylic acid (ASA) compounds,
corticosteroids, azathioprine/6-mercaptopurine, methotrex-
ate, cyclosporine, and anti-TNF𝛼 agents are constantly used
to manage these diseases. Several and probably less charac-
terized therapies, as additive to or alternative to conventional
therapies, in milder cases, aim to modulate gut microbiota,
directly or indirectly. For example, antibiotics are used in IBD,
and they are considered particularly effective in perianal and
postoperative CD and in pouchitis [18].
Probiotics contain viable organisms, sufficient amounts of
which reach the intestine in an active state, thus exert positive
health effects [19]. They mostly include lactic acid-producing
bacteria and yeasts that reach the gut unaltered, without
providing damage to the host [18, 20]. Their mechanisms of
action are still unclear; they probably modulate the mem-
brane permeability and themucosal immune system, keeping
away pathogens from intestinal mucosa surface. Lactobacillus
and Bifidobacteria produce harmful substances for Gram-
positive and Gram-negative bacteria, and they compete with
pathogens (i.e., Bacteriodetes, Clostridium, Staphylococcus,
and Enterobacter) for cell adhesion [18, 21, 22].
On the other side, prebiotics are selectively fermented
ingredients that allow specific changes both in the compo-
sition and/or in the activity of gastrointestinal microflora,
conferring benefits upon the host well-being and health
[19]. They are nondigestible oligosaccharides, such as fruc-
tooligosaccharides (FOS), galactooligosaccharides (GOS),
lactulose, and inulin, and they have the potential to stimulate
growth of selective and beneficial gut bacteria [18]. Because of
their composition, they cannot be adsorbed until they reach
colon, where they can be fermented by a specific microflora
into small chain fatty acid (SCFA) and lactate [23].
Their exact mechanism of action is still unclear. Recent
evidences hypothesized that they are able to increase the
production of SCFA and to modulate cytokines production
within the gut mucosa, by modulating the gut flora compo-
sition. The synergistic combination of pro- and prebiotics is
called “synbiotic” [19] (Figure 1).
2. Is There a Role for Specific Pathogens
in IBD?
It was originally suspected that IBD depend on a single
pathogenic strain of bacteria. In 1984, Chiodini et al. [24]
showed a strong association between Mycobacterium avium
subspecies paratubercalosis (MAP) and CD, but this hypoth-
esis was confirmed only by few studies. Furthermore, the
inefficiency of antituberculosis antibiotics in CD patients
reinforced the criticism towards MAP [25, 26].
Escherichia coli is usually isolated inmany intestinal biop-
sies of CD patients. In particular, adherent-invasive strains
(AIEC) are found in patients with ileal CD [27]. Also Yersinia
and Pseudomonas are supposed to act as triggers in CD
disease [28]. On the other side, Salmonella, Campylobacter
jejuni, Clostridiumdifficile, Adenovirus, andMycoplasmahave
been identified as agents associated to disease relapsing but
not to induction [29, 30].
A study conducted by Willing et al. [31] showed that,
in ileal CD patients, Faecalibacterium and Roseburia are
underrepresented whilst Enterobacteriaceae (such as E. coli)
and Ruminococcus gnavus are increased.
Fusobacterium varium has been localized in the colon of
UC patients and causes UC in mice when injected by enema
[32, 33]. Moreover, it has been assessed an overgrowth of
E. coli in UC patients, suggesting a possible role on genesis
and/or maintenance of the disease [34].
2.1. Is There a Role of the Commensal Flora in IBD Patho-
genesis? Several evidences support the hypothesis that gut
microbiota plays a role in the pathogenesis of IBD, particu-
larly studies involving animalmodels or in vitromodels. Here
we decided to present limited data coming from experimental
models, while focusing more on human studies.
Themost inflamed intestinal areas in IBD patients are the
same displaying the highest amount of intestinal bacteria.The
evidence that germ-free mice do not develop severe colitis
supports this finding [35]. Furthermore, recurrence rate of
postoperative CD and pouchitis is higher when the fecal
stream is reestablished [15, 36].
IBD patients display a reduced amount of dominant com-
mensal bacteria, such as Firmicutes (in particularClostridium
clusters IX and IV) and Bacteriodetes, facing an increased
number of Proteobacteria and Actinobacteria. This observa-
tion is associated with a decreased SCFA level in feces of IBD
patients. Among SCFAs, a decrease in butyrate level has been
associated with IBD as it is able to inhibit proinflammatory
cytokines release to increase the production of mucin and
antimicrobial peptides and to provide energy to colonocytes
[37–39].
Among Firmicutes, the reduction of Faecalibacterium
prausnitzii has recently emerged as a very frequent finding
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Figure 1: Gutmicrobiota in health condition and IBD and functions
of “the perfect probiotic”.
in CD; as shown in Sokol et al., administration of Faecal-
ibacterium prausnitzii has an anti-inflammatory activity, as
demonstrated by in vivo and in vitro studies [37].
Similar findings were obtained by Joossens et al. Fecal
microbiota of 68 CD patients, 84 unaffected relatives, and
55 controls were analyzed, and dysbiosis in CD patients was
found. In particular, it was assessed a reduction of Faecal-
ibacterium prausnitzii, Bifidobacterium adolescentis, Dialister
invisus, and of an unknown species of Clostridium clusters
XIVA, while Ruminococcus gnavuswas increased.This report
is the largest population study focused on gut microbiota
composition in IBD, where relatives represented controls
and differences were detectable despite common habits and
genetics. Moreover, a different microbiota composition was
assessed in IBD relatives compared to controls because of
the higher prevalence of bacteria with mucin degradation
capacity [40].
A different gutmicrobiota was found also in patients with
pouchitis compared to controls with a decreased concentra-
tion of Bacteriodetes and Faecalibacterium prausnitzii and an
increase in Proteobacteria [41, 42].
Furthermore, higher level of sulphate-reducing bacteria
(SRB) has also been observed in IBD, mainly in UC and
pouchitis patients. SRB are associated to a higher hydrogen
sulphide level, but to a less butyrate production. This is
supposed to induce cell hyperproliferation [43]. Interestingly,
SRB are supposed to be crucially important to induce DSS
colitis in mice [44]. Among these, a study conducted by
Rowan et al. [45] demonstrated an increased number of
Desulfovibrio subspecies in acute and chronic ulcerative coli-
tis with their products inhibited by the use of 5-aminosalycilic
acid [46].
The influence of microbiota in IBD is also supported by
the potential role of fecal transplantation, efficiently utilized
in severe Clostridium difficile infection, but also in IBD,
particularly in UC patients [47, 48].
On the other side, the importance of fungal flora in IBD
is still unclear.The presence of Saccharomyces Cerevisiae anti-
bodies in CDpatients offered a starting point for reflection on
the role of fungi in IBD pathogenesis. Enlarged populations
of Candida spp., Penicillium spp, and Saccharomyces sp. were
found in IBD patients compared to controls. However, more
studies are necessary to investigate whether fungal diversity
in IBD is a trigger for disease initiation or rather a secondary
effect of changes in bacterial composition and therapy [49]
(Table 1).
3. Does Appendectomy Affect the Clinical
Course of IBD?
A major role in the pathogenesis of IBD seems to be related
to the functions of cecal appendix, not to be considered
as a vestige [51], but rather one of the most important
immune organs along the gastrointestinal tract, as firstly
suggested by Berry [52]. Appendixmaintains the homeostasis
of gut microbial flora by producing and shedding biofilms
with the aim of modulating the epithelial regeneration and
protecting from pathogen microbes [53–55]. The big amount
of appendicular lymphoid tissue determines the introduction
into the cecal lumen of compounds such as mucin and
IgA. The evidence of an increased concentration of SIgA in
fecal samples of IBD patients—especially in CD patients—
toward healthy controls [56] confirms the central role of the
immune system in the pathogenesis of these inflammatory
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Table 1: Dysbiosis and IBD.
Bacteria CD UC References
Escherichia coli ↑ ↑ [27, 31, 34]
Pseudomonas ↑ [50]
Salmonella ↑ (relapsed) [29, 30]
Campylobacter jejuni ↑ (relapsed) [29, 30]
Clostridium difficile ↑ (relapsed) ↑ [29, 30, 47, 48]
Fusobacterium varium ↑ [32, 33, 37]
Clostridium cluster IX ↓ ↓ [37]
Clostridium cluster IV ↓ ↓ [37]
Faecalibacterium prausnitzii ↓ [31, 37, 40–42]
Bifidobacterium adolescentis ↓ [40]
Dialister invisus ↓ [40]
Ruminococcus gnavus ↑ [40]
Enterobacteriaceae ↑ ↑ [27, 31, 34]
Firmicutes ↓ ↓ [37, 39, 41, 42]
Bacteroidetes ↓ ↓ [37, 39, 41, 42]
Proteobacteria ↑ ↑ [37, 39, 41, 42]
Actinobacteria ↑ ↑ [37]
Sulphate-reducing bacteria (SRB) ↓ [43, 44, 46]
diseases. Several studies in literature try to solve the issue
of establishing the weight of appendix and appendectomy
in IBD. The majority of them support a highly significant
inverse relationship between appendectomy and the need
for surgery and immunosuppressant in UC patients [57–59],
with no significant variation in activity outcomes [60]. To
date, few studies about the relationship between appendix,
appendectomy, and CD show controversial results [61].
4. Which Role for Pre- and
Probiotics on the modulation of GUT
Microbiota Composition?
Gut microbiota modulation can be obtained with several
approaches, including antibiotics, pro- and prebiotics sup-
plementations, diet and correction of predisposing factors
responsible for gut microbiota alterations. Despite the sim-
plicity of this statement, few reports are really addressing
the ability of these factors to modulate gut microbiota
composition.
Venturi et al. reported that use of VSL#3 on 20 UC
patients intolerant or allergic with 5-ASA was associated
with an increase in fecal concentrations of Streptococcus
salivarius ssp. thermophilus, Lactobacilli, and Bifidobacteria,
which remained stable throughout the study. After 15 days
from discontinuation, levels returned similar to the basal
ones. Conversely, no change in fecal concentration of Bac-
teroides, Clostridia, coliforms, aerobic, and anaerobic bacteria
was reported [62]. Cui et al. demonstrated that treatment
with BIFICO induced an increase in Bacilli, Enterococci,
Bifidobacteria, and Lactobacilli, with a decrease of Bacteroides
and Bifidobacteria [63].
Finally, Welters et al. demonstrated a reduction in the
number of Bacteriodetes in feces of patients with chronic
pouchitis treated with 24 g per day of inulin [64].
The majority of the lines of evidence on the ability of
probiotics and prebiotics in modulating gut microbiota come
from indirect studies showing clinical efficacy of those in IBD,
which will be synthetically reported below.
5. Any Issues Related to the Methodology Used
for Studying Gut Bacteria?
Gut bacteria do not grow in regular culture media. That was
probably associated in the past with a clear underestimate of
gut microbiota role in human health and disease New tech-
niques involving culture-independent molecular techniques,
mostly related on analysis of 16S rDNA and including RT-
PCR, pyrosequencing, ormicroarray opened newhorizons in
this field [5–8]. The abundance of gut microbiota in human
body suggests that we are mostly made of bacteria [2], and in
the future we will probably realize that we are an image of the
balance between ourselves and bacteria within us.
6. Can the Modulation of Gut Microbiota
Cure IBD?
6.1. Probiotics and IBD. There are few studies on the efficacy
of probiotics in CD. These studies include a small number of
patients. Only one study is included in a Cochrane review
of randomized controlled trials. It compared the efficacy
of Lactobacillus GG toward placebo in CD patients. Eleven
patients were selected, only 5/11 completed the study, and
no significant differences were observed between the two
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Table 2: Probiotics and IBD.
Probiotics and IBD Aim Conclusion References
Lactobacillus GG Adjuvant to standard therapy in maintenance of remission in CD Useless [65–69]
Adjuvant to standard therapy in maintenance of remission in UC Effective [70]
VSL#3 Adjuvant to standard therapy in maintenance of remission in UC Effective [63, 71–73]
Prevention of pouchitis Effective [18, 74–76]
Saccharomyces boulardii Adjuvant to standard therapy in maintenance of remission in CD Effective [77]
groups [65]. In 2005, Bousvaros et al. conducted a random-
ized double-blind placebo controlled trial to establish the
efficacy of Lactobacillus GG as adjuvant to standard therapy
in the maintenance of remission in seventy-five CD patients.
No difference between the two groups was found [66].
Moreover, Saccharomyces boulardii showed positive effects on
maintaining a longer remission in CD [77] and improving the
intestinal barrier permeability [78]. Afterwards, a Cochrane
review, on seven studies [67], and a recentmeta-analysis [68],
on eight randomized placebo-controlled clinical trial, con-
firmed that probiotics are useless in maintaining remission
and preventing recurrence in CD. Their inefficiency is tested
also for postoperative CD [69].
For UC, a different scenario is described. The efficacy of
VSL#3 (Bifidobacterium breve, Bifidobacterium longum, Bifi-
dobacterium infantis, Lactobacillus acidophilus, Lactobacillus
plantarum, Lactobacillus paracasei, Lactobacillus bulgaricus,
and Streptococcus thermophilus) in UC patients was proved
in several papers. Bibiloni et al. studied 34 adult patients with
mild-moderate UC, in absence of adverse events [71]. Venturi
et al. assessed its positive effect on 20 UC patients intolerant
or allergic to 5-ASA [62]. VSL#3 efficacy was also tested in a
study conducted on children with newly diagnosed UC [72].
In 2004, Kruis et al. showed that therewas no difference in the
use of the probiotic E. coli Nissle 1917 and mesalazine in the
maintenance of remission in UC patients. On the other side,
Cui et al. demonstrated the efficacy of BIFICO in preventing
flares in UC patients [63, 73]. In 2006, another study showed
the efficacy of Lactobacillus GG in maintenance of remission
in 187UCpatients [70]. In 2007, in a Cochrane review,Mallon
et al. [79] concluded that probiotics could provide efficacy in
themaintenance of remission in patients withmild-moderate
UC, while limited efficacy could be predicted for moderate-
severe disease.Despite these positive results about the efficacy
of probiotics in the maintenance of remission in UC, further
studies are necessary [74, 80].
In pouchitis, Gionchetti et al. sustained VSL#3 efficacy
in a study conducted on 40 patients with ileal pouch-anal
anastomosis. Twenty patients receivedVSL#3 and 20 received
placebo: only 10% of patients that received VSL#3 developed
pouchitis versus 40% of placebo patients [75]. Mimura et al.
confirmed these data [76].
Based on this, VSL#3 is approved for the prevention and
the maintenance of remission of pouchitis, and the efficacy is
stated also in referral European guidelines [18, 74] (Table 2).
6.2. Prebiotics and IBD. The efficacy of prebiotics in IBD is
mostly confined to in vitro [87] and animal models (DSS
and TNBS-induced colitis) studies [88–91]. However, there
are also few human studies that include a small number of
patients.
One of the first studies conducted involved 10 CD
patients receiving 15 g of fructooligosaccharides (FOS). In
these patients, the disease activity index was reduced, and
mucosal Bifidobacteria were increased [81]. The efficacy of
FOS in CD was also tested by Benjamin et al. in a study
published in 2011. On hundred and three CD patients were
randomized to receive 15 g/day FOS or placebo for 4 weeks.
There was no significant clinical improvement in patients
receiving FOS, but they had reduced proportions of inter-
leukin (IL)-6-positive lamina propria dendritic cells (DC)
and increased DC IL-10 staining. There was no change in
IL-12p40 production. Significant difference in the number of
Bifidobacteria and F. prausnitzii in feces was not observed
[82].
In 2002, Bamba et al. demonstrated a potential role of
germinated barley foodstuff (GBF) in inducing remission
in patients with mild to moderate active ulcerative colitis
[83]. The same result was confirmed by a study conducted
by Kanauchi et al. [84]. The potential efficacy of another
prebiotic, Ispaghula husk, was found by Hallert et al. [85]. A
prospective, randomized, placebo controlled pilot trial on 19
UC patients treated with mesalazine showed that the group
who received oligofructose-enriched inulin supplementation
had a lower fecal calprotectin than controls. Fecal calprotectin
is an inflammatory marker, so we can suppose that prebiotics
can reduce inflammation in UC patients [86].
Furthermore, Welters et al. demonstrated that inulin
supplementation in pouchitis was associated to a lower
inflammation indicated by an increased level of butyrate, a
lower concentration of Bacteroides fragilis and secondary bile
acids in feces, and a reduced endoscopic inflammation [64]
(Table 3).
7. Limitations and Future Perspectives
Nevertheless, several doubts and limitations remain
unsolved. Gut microbiota composition in healthy individuals
is still unclear. There are no studies with a primary aim
focused on a specific therapy towards the modifications
of gut microbiota. Probiotics use is often not evidence
based because mechanisms of action are still unclear, such
as intestinal bioavailability of bacterial strains, dose, and
treatment time. Moreover, useful methods for gut microbiota
characterization have high cost and are not standardized.
Future practice will probably provide a gut microbiota
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Table 3: Prebiotics and IBD.
Prebiotics and IBD Aim Conclusion References
15 g fructooligosaccharides (FOS) Reduction of disease activity index Controversial data [81, 82]
Germinated barley foodstuff (GBF) Remission in patients with mild-to-moderate active UC Effective [83, 84]
Ispaghula husk Remission in patients with mild-to-moderate active UC Effective [85]
Oligofructose with inulin Reduction of inflammation in UC Effective [86]
Inulin Reduction of inflammation in pouchitis Effective [64]
characterization, which will be useful for different types
of application. Pre- and/or probiotic therapy will consist
in supplementation of specific subset of bacterial strains,
which will provide the desired variation in gut microbiota
composition.
8. Conclusions
Gutmicrobiota plays a crucial role in triggering,maintaining,
and exacerbating IBD. Specific microbes can be overrepre-
sented in IBD while others seem to be protective. A decrease
in microbial biodiversity has been found in mucosa and feces
of IBD patients, together with an increase of fungi.
Pre- and probiotics could represent a valid armamentar-
ium to modulate gut microbiota and, probably, to cure IBD.
Current evidences, however, show a clear clinical efficacy of
some families of probiotics only in pouchitis and ulcerative
colitis but not in Crohn’s disease. This efficacy has been
prevalently associated to mild disease and seems to have
a better role in maintenance of remission compared to
induction of remission.
Further studies are necessary to better characterize the
exact role of probiotics in IBD, their specific mechanisms of
actions, including a direct effect on mucosal homeostasis or
healing. Since probiotics are becoming a legitimate therapeu-
tic option, it is necessary to determinewhich probiotic strains
have the greatest efficacy, whether they are more effective
alone, or in conjunction with other pro- or prebiotics, and
what is their half-life in the gastrointestinal tract. On the base
of these data, frequency of administration and dose could be
exactly calculated.
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